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ABSTRACT
Objective To determine the effectiveness of vitamin D
supplementation for improving bone mineral density in
children and adolescents and if effects vary with factors
such as vitamin D dose and vitamin D status.
Design Systematic review and meta-analysis.
Data sources Cochrane Central Register of Controlled
Trials, Medline (1966 to present), Embase (1980 to
present), CINAHL (1982 to present), AMED (1985 to
present), and ISI Web of Science (1945 to present), last
updated on 9 August 2009, and hand searching of
conference abstracts from key journals.
Study selection Placebo controlled randomised
controlled trials of vitamin D supplementation for at least
three months in healthy children and adolescents (aged
1 month to <20 years) with bone density outcomes. Two
authors independently assessed references for inclusion
and study quality and extracted data.
Data synthesis Standardised mean differences of the
percentagechangefrombaselinein bonemineraldensity
oftheforearm,hip,andlumbarspineandtotalbodybone
mineral content in treatment and control groups.
Subgroup analyses were carried out by sex, pubertal
stage, dose of vitamin D, and baseline serum vitamin D
concentration. Compliance and allocation concealment
were also considered as possible sources of
heterogeneity.
Results From 1653 potential references, six studies,
totalling 343 participants receiving placebo and 541
receiving vitamin D, contributed data to meta-analyses.
Vitamin D supplementation had no statistically
significant effects on total body bone mineral content or
onbonemineraldensityofthehiporforearm.Therewasa
trend to a small effect on lumbar spine bone mineral
density (standardised mean difference 0.15, 95%
confidence interval −0.01 to 0.31; P=0.07). Effects were
similarinstudiesofparticipantswithhighcomparedwith
low serum vitamin D levels, although there was a trend
towards a larger effect with low vitamin D for total body
bone mineral content (P=0.09 for difference). In studies
withlowserumvitaminD,significanteffectsontotalbody
bone mineral content and lumbar spine bone mineral
density were roughly equivalent to a 2.6% and 1.7%
percentage point greater change from baseline in the
supplemented group.
Conclusions It is unlikely that vitamin D supplements are
beneficial in children and adolescents with normal
vitamin D levels. The planned subgroup analyses by
baseline serum vitamin D level suggest that vitamin D
supplementation of deficient children and adolescents
couldresultinclinicallyusefulimprovements,particularly
inlumbarspinebonemineraldensityandtotalbodybone
mineral content, but this requires confirmation.
INTRODUCTION
Prevention of the common
1 and costly
2 public health
problem of osteoporosis is of great importance. Low
bone mineral density is a major risk factor for osteo-
poroticfracture.
3Peakbonemassandrateofboneloss
both impact on bone mineral density in later life
4 and
are equally important risk factors for osteoporotic
fracture.
5 A 10% increase in peak bone mass is esti-
mated to halve the risk of an osteoporotic fracture in
adult life.
6 Low bone mineral density is also a risk fac-
tor for fracture in childhood.
7-9 Strategies to maximise
peak bone mass in children have been identified as a
priority area for research.
10
One such potential strategy is to improve vitamin D
levels in children. Vitamin D deficiency is diagnosed
by measurement of serum 25-hydroxyvitamin D.
11
Concentrations above 50 nmol/L are considered nor-
mal, but there is debate about the level of this
threshold
12 because although only lower levels are
usually associated with clinical disease such as rickets,
the optimal level for bone health may be above 50
nmol/L. A low vitamin D level in children and adoles-
cents is common enough to be an important public
health issue globally across a range of latitudes,
including the United Kingdom,
1314 other European
countries,
15-20 the United States,
21 Lebanon,
22
Australia,
2324 and New Zealand.
112526 Overt vitamin
D deficiency leads to rickets, and subclinical vitamin
D deficiency may also affect bone mineralisation, as
assessed by dual x ray absorptiometry.
151727-29 Rando-
mised controlled trials of vitamin D supplementation
have, however, reported inconsistent results for bone
densitometry measures,
2730-34 and therefore the effec-
tiveness of vitamin D supplementation for improving
bone density is unclear.
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the effectiveness of vitamin D supplementation for
improving bone density in healthy children and ado-
lescents,toidentifyfactorsmodifyinganyeffect,andto
determine if any effect persists after supplementation
ceases.
METHODS
The protocol for this review is published elsewhere.
35
Studies were eligible for inclusion if they were rando-
misedplacebocontrolledtrialsofatleastthreemonths
of vitamin D supplementation, were carried out in
healthy children or adolescents aged between
1 month and 20 years, and measured primary out-
comes of areal or volumetric bone mineral density,
bone mineral content, or quantitative ultrasound mea-
sures (broadband ultrasound attenuation, speed of
sound, stiffness index).
Although fractures in later life would be the ideal
outcome measure, this would require following large
numbers of children as participants for decades. No
such studies have been done, so we used bone density
measures as surrogate outcomes, as is commonly seen
in children.
36 Bone mineral density and content
7-9 and
quantitative ultrasound measures
37 have all been asso-
ciated with fracture risk.
Identification of studies
The electronic literature search was last updated on 9
August 2009. Without language restrictions, we
searched the Cochrane Central Register of Controlled
Trials,Medline(1966topresent),Embase(1980topre-
sent),CINAHL(1982topresent),AMED(1985topre-
sent), and ISI Web of Science (1945 to present). Web
extra appendix 1 gives the search strategy used for
Medline, which was adapted as appropriate for other
databases.
We hand searched conference abstract issues of key
journals for 2007-8: Osteoporosis International, Journal of
Bone and Mineral Research, Asia Pacific Journal of Clinical
Nutrition,JournaloftheAmericanDieteticAssociation,Pro-
ceedings of the Nutrition Society, Journal of Nutrition.W e
examined the reference lists and ISI citations of all
included studies. Two reviewers assessed potentially
relevant articles against the inclusion criteria.
Data collection and analysis
Tworeviewersindependentlyextracteddata.Weextra-
cted change in bone mineral density and bone mineral
content as percentage change from baseline, as well as
sex, age, pubertal stage, baseline serum vitamin D
levels, ethnicity, type and dose of vitamin D given,
and compliance as possible effect modifiers, along
with data on adverse events. No studies reported quan-
titative ultrasound outcomes. Two reviewers indepen-
dentlyassessed each trial’srisk ofbias, assessingfactors
such as randomisation, allocation concealment, blind-
ing,completenessofoutcomeassessment,andselective
reporting. Where necessary we contacted authors to
obtain information on primary outcome factors.
We converted bone density outcomes to standar-
dised mean differences, calculating a standardised
mean difference of the percentage change from base-
line in treatment and control groups at each site for
which there were sufficient data (bone mineral density
forforearm,hip,andlumbarspineandtotalbodybone
mineralcontent).Whereclinicallyuseful,weestimated
a benefit in units of percentage change since baseline
from the standardised mean differences by estimating
the pooled standard deviation from the means of the
standard deviation of the outcomes in treatment and
control groups for each study, and multiplying the
standardised mean differences by this.
38-40
Wecalculatedstatistical heterogeneityusingaχ
2test
onN-1degreesoffreedom,withsignificanceconserva-
tively set at 0.10. We also assessed inconsistency I
2
using the formula [(Q-df)/Q]×100%, where Q is the χ
2
statisticanddfisitsdegreesoffreedom,todescribethe
percentage of the variability in effect estimates due to
heterogeneity. We considered a value greater than
50% as denoting substantial heterogeneity.
Meta-analysis was done according to a fixed effects
model. When heterogeneity was considered substan-
tial,weexploreditscausesbycarryingoutprespecified
subgroup analyses where data were available—that is,
subgroups by sex, pubertal stage, dose of vitamin D,
baseline vitamin D levels, compliance, and adequacy
Table 1 |Characteristics of studies included in meta-analysis
Study
Cholecalciferol
dose
Duration
(years) No Ethnicity
Pubertal
stage
Female
(%)
Mean (range) age
(years)
Baseline serum
vitamin D level
(nmol/L) Site measured*
Andersen 2008
52 400 or 200 IU/day 1 26 Pakistani NS 100 12.2† (10.1-14.7) 7.3-16.9 Lumbar spine, total body
Cheng 2005
27 200 IU/day 2 98 White Prepubertal 100 11.1 (10-12) 49.5 Hip, lumbar spine, total body
Du 2004
32 132 IU/day 2 498 Chinese Mixed 100 10.1 (NS) 17.7-20.6 Forearm, total body
El Hajj Fuleihan 2006
33 54:
Males 1400 IU/week
or 14 000 IU/week
1 184 NS Mixed 0 13.0 (10-17) 40 Lumbar spine, hip, 1/3 radius,
total body
Females 1400 IU/week
or 14 000 IU/week
1 179 NS Mixed 100 13.2 (10-17) 34.9 Lumbar spine, hip, 1/3 radius,
total body
Viljakainen 2006
34 400 or 200 IU/day 1 228 White 100 11.4 (11-12) 47 Lumbar spine, hip
NS=Not specified.
*Further details of measures in Cochrane review.
53
†Median.
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consider ethnicity and sun exposure as possible
sources of heterogeneity, as planned in the original
protocol. Where there were not clear clinical reasons
or study methodology reasons for substantial hetero-
geneity between studies, we proceeded to meta-
analysis using random effects models. All analyses
werecarriedoutinReviewManager5(version5.0.16).
We performed a priori subgroup analyses by sex,
pubertalstage,doseofvitaminD,andbaselinevitamin
D levels to determine whether the effects of supple-
mentation varied by these factors. As the numbers of
studiesweresmall,thecut-offsof200 IUforvitaminD
doseand 35 nmol/Lfor baselinevitamin D concentra-
tions were chosen on the basis of their being sufficient
data available at these cut-offs to allow for subgroup
analyses. When possible we used intention to treat
data in analyses, but if these were not available we
used, in order of preference, data from available data
or per protocol analyses. Assessment of publication
bias was by funnel plot.
Where studies had more than one vitamin D dosage
group, we combined the data from all dosage groups
Bone mineral density of hip
  Cheng 200527
  El-Hajj Fuleihan (M) 2006
33 54
  El-Hajj Fuleihan (F) 2006
33
  Viljakainen 200634
Total (95% CI)
Test for heterogeneity: τ2=0.03, χ2=6.09, df=3, P=0.11, I2=51%
Test for overall effect: z=0.46, P=0.64
Bone mineral density of lumbar spine
  Andersen 2008
52
  Cheng 200527
  El-Hajj Fuleihan (M) 200633 54
  El-Hajj Fuleihan (F) 200633
  Viljakainen 200634
Total (95% CI)
Test for heterogeneity: χ2=5.02, df=4, P=0.28, I2=20%
Test for overall effect: z=1.84, P=0.07
Total body bone mineral content
  Andersen 200852
  Cheng 200527
  Du 200432
  El-Hajj Fuleihan (M) 2006
33 54
  El-Hajj Fuleihan (F) 200633
Total (95% CI)
Test for heterogeneity: χ2=4.05, df=4, P=0.40, I2=1%
Test for overall effect: z=1.26, P=0.21
Bone mineral density of forearm
  Cheng 200527
  El-Hajj Fuleihan (M) 2006
33 54
  El-Hajj Fuleihan (F) 200633
Total (95% CI)
Test for heterogeneity: τ2=0.09, χ2=7.82, df=2, P=0.02, I2=74%
Test for overall effect: z=0.21, P=0.84
Treatment group Control
14.2 (1.0)
4.0 (4.5)
4.4 (4.6)
8.2 (6.5)
13.2 (10.9)
19.2 (1.0)
9.7 (6.7)
8.6 (7.4)
11.6 (6.2)
15.4 (12.0)
34.7 (1.3)
39.7 (8.5)
15.9 (8.4)
11.6 (10.8)
3.4 (1.4)
3.0 (3.3)
3.5 (3.9)
Mean (SD)
46
116
113
139
414
14
46
116
113
139
428
14
46
113
116
113
402
46
116
113
275
Total
14.5 (1.0)
4.3 (4.6)
3.2 (4.3)
6.7 (6.4)
9.6 (7.5)
19.4 (1.1)
9.6 (6.7)
6.5 (5.2)
9.7 (7.8)
12.7 (7.6)
35.0 (1.4)
38.4 (6.7)
15.8 (8.4)
8.7 (8.8)
2.6 (1.5)
3.9 (4.2)
3.7 (2.7)
Mean (SD)
41
56
55
73
225
7
41
56
55
73
232
7
41
111
56
55
270
41
56
55
152
Total
-0.30 (-0.72 to 0.13)
-0.07 (-0.39 to 0.25)
0.25 (-0.07 to 0.58)
0.23 (-0.06 to 0.51)
0.06 (-0.18 to 0.29)
0.34 (-0.57 to 1.26)
-0.19 (-0.61 to 0.23)
0.01 (-0.31 to 0.33)
0.30 (-0.02 to 0.63)
0.28 (-0.00 to 0.56)
0.15 (-0.01 to 0.31)
0.24 (-0.67 to 1.15)
-0.22 (-0.64 to 0.20)
0.15 (-0.11 to 0.42)
0.01 (-0.31 to 0.33)
0.29 (-0.04 to 0.61)
0.10 (-0.06 to 0.26)
0.51 (0.08 to 0.93)
-0.25 (-0.57 to 0.07)
-0.06 (-0.38 to 0.26)
0.04 (-0.36 to 0.45)
19.2
26.1
25.8
28.9
100.0
3.1
14.6
25.5
24.7
32.1
100.0
3.0
13.8
35.7
24.1
23.4
100.0
29.9
35.1
35.0
100.0
-2 -1 0 1 2
Study or subgroup
Favours
control
Favours
treatment
Standard mean difference
IV, random/fixed* (95% CI)
Standard mean difference
IV, random/fixed* (95% CI)
Weight
(%)
Forest plots of main effects of vitamin D supplementation on bone mineral density of hip, lumbar spine, and forearm, and total
body bone mineral content. M=males; F=females. *Fixed model used for lumbar spine bone mineral density and total body
bone mineral content. See web extra for data to two decimal places
Table 2 |Main effects of vitamin D supplementation
Outcome No of studies
No of
participants
Standardised mean
difference* (95% CI)
Hip bone mineral density 4 639 0.06 (−0.18 to 0.29)
Lumbar spine bone mineral density 5 660 0.15 (−0.01 to 0.31)†
Total body bone mineral content 5 672 0.10 (−0.06 to 0.26)
Forearm bone mineral density 3 563 0.04 (−0.36 to 0.45)
Outcome is percentage change from baseline.
*Standardised mean difference of 0.3 regarded as small.
59
†P=0.07.
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wasinsubgroupanalysesbyvitaminDdose—forthose
studies with a dosage group falling into each subgroup
we used the data from the individual dosage group for
the treatment arms and used the control group mean
and standard deviation for each subgroup comparison
but reduced the number in the control groups by half
for each comparison.
Onestudywasaclusterrandomisedcontrolledtrial,
32
with data that did not account for clustering. We used
the subsequently published intracluster correlation for
totalbodybonemineral content
41 ina sensitivity analy-
sis,correcting the sample size for the effect ofclustering
by the design effect of 1.946, calculated by 1+(M−1)
ICC,whereMistheclustersizeandICCtheintracluster
correlation (87 and 0.011, respectively).
RESULTS
The search identified 1653 references, of which 1599
were excluded at initial independent screening of the
title and abstract (κ=0.66), with 25 disagreements. The
disagreements were resolved by consensus and all 25
were excluded at screening of the abstract. Six refer-
ences were in German. These were excluded after
assessment by a rheumatologist fluent in German in
conjunction with one author.
Of the 23 references requiring full text review, 12
references to seven studies were included (see web
extra appendix 2). Studies were excluded for several
reasons: not randomised controlled trials (four
studies),
42-45 participants not within age range 1 month
to 20 years (three studies),
46-48 bone density outcomes
not measured (two studies),
4950 no vitamin D inter-
vention (one study),
51 and not placebo controlled trial
(onestudy).
16Onestudywasexcludedfornotreporting
av a r i a n c em e a s u r e .
30 This study was small (n=60) and
reported noeffectofsupplementationfor bonemineral
content at the distal one third of the radius.
The meta-analysis used data from six studies, with
343 participants receiving placebo and 541 receiving
vitamin D (table 1).
2731-3452 The full review provides
more detailed information on these studies.
54 Partici-
pants were aged from 8 to 17 years. Bone density was
measured by dual x ray absorptiometry in all studies
except one in which volumetric bone mineral density
was measured using peripheral quantitative computed
tomographyatthedistalradius.
27Nostudiesmeasured
quantitative ultrasound outcomes. All studies
administered vitamin D3 (cholecalciferol), with the
dose ranging from 132 IU daily
32 to 14000 IU per
week
3133 over one
31333452 or two
2732 years. One study
provided follow-up data for three years after
supplementation.
32 Two studies included cointerven-
tions,oneofmilk,providinganaverageof245mg/day
of calcium to both control and supplement groups,
32
and one of 1000 mg/day of calcium carbonate in both
vitamin D and control groups.
27 Mean baseline serum
vitamin D levels ranged from 17.7 to 49.5 nmol/L.
Results from available data analysis were extracted
for all studies except one,
32 which reported per proto-
col analysis, excluding 33 participants with poor com-
pliance.
Risk of bias
One study had clearly documented and adequate
sequence generation, allocation concealment, blind-
ing, and reasons for withdrawals.
27 Two other studies
described adequate sequence generation and alloca-
tion concealment,
313354 and in the remainingthreestu-
dies these were unclear.
323452 All studieswere stated to
bedoubleblind,althoughtheblindingprocesswasnot
fully described. The risk of bias from this was, how-
ever, assessed as very low as it is unlikely that bone
densityoutcomescouldbeinfluencedbylackofblind-
ing.Nostudyreportedimputingformissingdatainthe
analysis, but loss to follow-up was for the most part
either evenly distributed across groups
31335254 or rea-
sons for withdrawal were stated and unlikely to be
related to the true outcome.
2734 Incomplete outcome
data posed a risk of bias in one study in which forearm
bonemineraldensitywasmeasuredbutnotreported.
32
Although the number of studies was small, funnel
plots suggested that publication bias was not present
(data not shown, see full review for details
53).
Effects of interventions
Table 2givesthemaineffectsofvitaminDsupplemen-
tation at different sites (see also figure). Overall, vita-
min D supplementation did not have statistically
significant effects on percentage change in total body
bone mineral content or bone mineral density of the
hip or forearm. There was a trend to a small effect on
lumbarspinebonemineraldensity(standardisedmean
difference0.15,95%confidenceinterval−0.01to0.31,
P=0.07). The results for percentage change were statis-
tically heterogeneous for bone mineral density of the
Table 3 |Subgroup analyses of effects of vitamin D supplementation by sex
Outcome
Females Males
No of studies
No of
participants
Standardised mean difference*
(95% CI) No of studies
No of
participants
Standardised mean difference*
(95% CI)
Hip bone mineral density 3 467 0.09 (−0.21 to 0.40) 1 172 −0.07 (−0.39 to 0.25)
Lumbar spine bone mineral density 4 488 0.20 (0.01 to 0.39)† 1 172 0.01 (−0.31 to 0.33)
Total body bone mineral content 4 500 0.13 (−0.05 to 0.31) 1 172 0.01 (−0.31 to 0.33)
Forearm bone mineral density 2 255 0.20 (−0.35 to 0.76) 1 172 −0.25 (−0.57 to 0.07)
Outcome is percentage change from baseline.
*Standardised mean difference of 0.3 regarded as small.
59
†Statistically significant at 5% level.
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2=6.09, df=3, P=0.11, I
2=51%) and forearm
(χ
2=7.82, df=2, P=0.02, I
2=74%) but not at other sites.
The use of data on total body bone mineral content
correctedforclustereffects
3241didnotmateriallyaffect
the result (total body bone mineral content standar-
dised mean difference 0.09, −0.08 to 0.26).
Heterogeneity
Sex, baseline serum vitamin D level, and adequacy of
allocation concealment did not explain heterogeneity
seen between studies for analyses of hip and forearm
bone mineral density. One study comprised males
only. Heterogeneity was still significant in studies in
females (hip: χ
2=4.94, df=2, P=0.08, I
2=60%; forearm:
χ
2=4.32, df=1, P=0.04, I
2=60%). One study with out-
comes for hip and forearm bone mineral density com-
prisedparticipantswithameanbaselineserumvitamin
D concentration less than 35 nmol/L. Significant het-
erogeneity remained in those studies with participants
who had a baseline serum vitamin D concentration
above this level (hip: χ
2=4.54, df=2, P=0.10, I
2=56%;
forearm:χ
2=7.66,df=1,P=0.006,I
2=87%).Insubgroup
analysis by allocation concealment (adequate com-
pared with inadequate or unclear) heterogeneity
remained in the adequate allocation concealment sub-
group for hip bone mineral density (χ
2=4.47, df=2,
P=0.11,I
2=55%).Nostudieshadinadequateorunclear
allocation concealment for forearm bone mineral den-
sity, so subgroup analysis could not be done.
Classification of studies into subgroups by compli-
ance and by pubertal status of participants in the
study as a whole resulted in identical subgroups.
Only one study was in purely prepubertal children,
27
and this was the only study with low compliance. All
other studies were in children and adolescents of
mixed pubertal status with high compliance. In the
mixed pubertal stage and high compliance subgroup,
heterogeneitywasnotsignificantateitherthehiporthe
forearm (χ
2=2.55, df=2, P=0.28, I
2=22%; and χ
2=0.64,
df=1, P=0.42, I
2=0%).
Subgroup analyses for differences in effects
The effects of supplementation at all sites were similar
regardless of vitamin D dose given (>200 IU daily v
≤200 IU daily; data not shown, see full Cochrane
review for details
54) and sex (table 3). In females but
notinmales,however,theeffectonlumbarspinebone
mineral density was statistically significant. There was
a trend for larger effect in the low serum vitamin D
subgroup of studies for total body bone mineral con-
tent (P=0.09 for subgroup difference), but effects were
similar between low and high serum vitamin D groups
at other sites (table 4). In the low serum vitamin D
studies,however,theeffectfortotalbodybonemineral
contentwassignificant(P=0.04),andtheresultforlum-
bar spine bone mineral density bordered on signifi-
cance (P=0.05).
Vitamin D supplementation had a greater effect for
forearmbonemineraldensityinstudiesinprepubertal
andlowcompliancechildren(table 5)butthedirection
of this effect was the opposite of that observed at other
sites.Wealsocomparedeffectsinprepubertal(Tanner
stage 1 or 2) and postpubertal (Tanner stage 3 and 4)
young people derived from within individual studies.
These did not show any significant differences in
effects between groups at any site (table 6).
Sensitivity analyses
Correctingforintraclustercorrelationinonestudydid
not materially affect the results for total body bone
mineral content(datanot shown).
32In lightof the find-
ings about the explanatory effect for heterogeneity in
Cheng 2005,
27 subgroup analyses were repeated by
sex, baseline serum vitamin D level, dose of cholecal-
ciferol,and adequacyof allocation concealment, omit-
ting this study where there was heterogeneity within
any subgroup. This was possible only for hip bone
mineral density owing to the number of studies
involved. This reduced heterogeneity to non-signifi-
cant levels. An effect on hip bone mineral density in
females was found (standardised mean difference
0.24, 95% confidence interval 0.03 to 0.45, P=0.03),
which was not seen when Cheng 2005 was included,
buttheeffectsizewasstillsimilarinbothsexes.Results
ofanalysesforhipbonemineraldensitybyserumvita-
min D level, dose of cholecalciferol, and allocation
concealment were similar to those of the analyses
including Cheng 2005 (data not shown).
Benefits after supplementation ceases
One study
3255 provided follow-up data after supple-
mentation ceased. Total body bone mineral content
Table 4 |Subgroup analyses of effects of vitamin D supplementation by baseline serum vitamin D level
Outcome
Low baseline vitamin D level (<35 nmol/L) High baseline vitamin D level (≥35 nmol/L)
No of studies
No of
participants
Standardised mean difference*
(95% CI) No of studies
No of
participants
Standardised mean difference*
(95% CI)
Hip bone mineral density 1 168 0.25 (−0.07 to 0.58) 3 471 −0.02 (−0.31 to 0.28)
Lumbar spine bone mineral density 2 189 0.31 (0.00 to 0.61)† 3 471 0.09 (−0.10 to 0.28)
Total body bone mineral content 3 413 0.21 (0.01 to 0.41)‡ 2 259 −0.07 (−0.33 to 0.18)§
Forearm bone mineral density 1 168 −0.06 (−0.38 to 0.26) 2 259 0.12 (−0.62 to 0.85)
Outcome is percentage change from baseline.
*Standardised mean difference of 0.3 regarded as small.
59
†P=0.05.
‡Statistically significant at 5% level.
§P=0.09 for difference.
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milk and the group receiving calcium and vitamin D
supplemented milk did not differ significantly three
years after supplementation ceased (percentage
change since baseline 71.9 (SD 1.5) and 70.8 (SD 1.5),
respectively).
Adverse events
Reporting of adverse events was limited but suggested
that vitamin D supplementation is well tolerated. No
children developed hypercalcaemia in one study.
52 In
another study, four children dropped out through dis-
ease onset described as unrelated to the trial, but gave
no further details.
27 In another, one child withdrew
owing to skin allergy, but the intervention arm to
which the child belonged and potential relationship
to vitamin D was not reported.
32 One study reported
that treatment was well tolerated,
33 with two partici-
pantsintheplacebogrouphavingincreasedserumcal-
cium levels at the end of one year, and one girl who
received cholecalciferol 1400 IU/week developing
post-streptococcal glomerulonephritis. In boys, three
participants in the placebo group and one in each vita-
min dose group had increased serum calcium levels at
one year.
3354 The final study reported that 16 children
dropped out for reasons not related to the study proto-
col, but gave no further details.
34
DISCUSSION
Thissystematicreviewindicatesthattargetingchildren
and adolescents with low serum vitamin D concentra-
tions could result in clinically important improve-
ments in bone density but that vitamin D
supplementation in healthy children and adolescents
generally to improve bone density is not justified.
Clinical and policy implications
Although it is difficult to extrapolate bone density out-
comes in childhood to reduction in risk of fracture in
adulthood, our results suggest that it is plausible that
vitamin D supplementation in deficient children and
adolescents can deliver clinically significant improve-
ments in bone health. For example, the magnitude of
thestandardisedmeandifferencesofeffectsinchildren
and adolescents with low baseline serum vitamin D
concentrations were 0.21 for total body bone mineral
content, 0.31 for lumbar spine bone mineral density,
and 0.25 for hip bone mineral density, all of which
were at least 0.2 standardised mean differences higher
than in children and adolescents with high baseline
vitamin D levels. This standardised mean difference
is about equivalent to a 2.6% point greater change in
total body bone mineral content from baseline in the
vitamin D supplemented group than in the control
group. Equivalent estimates were 1% for hip bone
mineral density and 1.7% for lumbar spine bone
mineral density. Effects at the forearm were neither
statisticallynorclinicallysignificant.Theavailablestu-
dies did not allow us to ascertain whether the effects of
supplementation accumulate while supplementation
continues or if the effect plateaus over time. However,
if a 10% increase in peak bonemass can, aspostulated,
reduce the risk of an osteoporotic fracture in adult life
by 50%,
6 an effect on fracture risk in later life of both
clinical and public health significance is achievable,
particularly if effects do accumulate. Children with
wrist and forearm fractures have a bone mineral den-
sity up to 8% lower than children without such
fractures.
7-9 We estimate that a 5% increase in total
body bone mineral density and bone mineral density
of the hip or lumbar spine could decrease the relative
risk of fracture in childhood by about 17% and 9%,
respectively.
9 Thus, vitamin D supplementation has
the potential to have a substantial effect on adult frac-
ture rates and an effect in childhood.
In light of these data, the approach to addressing
vitamin D deficiency in children and adolescents war-
rants further consideration. Possible choices include
fortificationoffoodordirectsupplementationateither
population or individual level. In trials of increasing
vitamin D intake in children, whether through fortifi-
cation of food or supplements, it is possible to achieve
increases in serum vitamin D levels, but the doses of
cholecalciferol required to correct deficiency and
reach post-intervention vitamin D concentrations
above 50 nmol/L are in excess of 400 IU/day.
56
Thus, while food fortification may offer some protec-
tion against vitamin D deficiency in children,
57 it is
unlikelyasufficientdosecouldbedeliveredtoachieve
adequate serum levels in children with deficiency.
Unfortunately, the alternative of screening for vitamin
D deficiency and then correcting it is more costly and
relatively invasive. The cost effectiveness and accept-
ability of screening remains to be established,
Table 5 |Subgroup analyses of effects of vitamin D supplementation by pubertal status and compliance
Outcome
Prepubertal and low compliance Mixed pubertal and high compliance
No of studies
No of
participants
Standardised mean difference*
(95% CI) No of studies
No of
participants
Standardised mean difference*
(95% CI)
Hip bone mineral density 1 87 −0.30 (−0.72 to 0.13) 3 552 0.14 (−0.3 to 0.32)
Lumbar spine bone mineral density 1 87 −0.19 (−0.61 to 0.23) 4 573 0.21 (0.04 to 0.38)†‡
Total body bone mineral content 1 87 −0.22 (−0.64 to 0.20) 4 585 0.15 (−0.02 to 0.32)
Forearm bone mineral density 1 87 0.51 (0.08 to 0.93)† 2 340 −0.16 (−0.38 to 0.07)
Outcome is percentage change from baseline.
*Standardised mean difference of 0.3 regarded as small.
59
†Statistically significant at 5% level.
‡P=0.09 for difference.
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trials to assess the benefits of doing so for bone health.
Potential effect modifiers
Besides baseline serum vitamin D levels, other poten-
tial modifiers of the effect of vitamin D supplementa-
tion include sex, pubertal status, and compliance,
although the paucity of evidence available to examine
potentialeffectmodificationmeansthatdefinitivecon-
clusions cannot be drawn. Based on the current evi-
dence, it may be that vitamin D deficient females are
the subgroup likely to have the greatest response to
supplementation, but the paucity of data in males
means that this is not certain. The average baseline
vitamin D concentration in males was 5 nmol/L
lower than that of females, which could contribute to
any difference. Unfortunately, studies of subgroups of
prepubertal compared with mixed pubertal stages and
those oflow and highcompliancewere identical,mak-
ing it difficult to separate effects of these factors. How-
ever, when participants were divided within studies
intoprepubertal(Tannerstage1or2)andpostpubertal
(Tanner stage 3 or 4) groups, the effects between sub-
groups did not differ, suggesting that compliance,
ratherthanpubertalstage,ismorelikelytobeaneffect
modifier.Thedirectionofeffectwasinconsistentatthe
forearm compared with other sites in the analysis by
pubertal status and compliance subgroups. For fore-
arm bone mineral density the overall effect was 0.67,
favouringthecontrolgroupintheprepubertalandlow
compliance study
27 but the direction of effects
favoured vitamin D supplementation at the hip, lum-
bar spine, and total body bone mineral content. This
couldreflectgenuinedifferencesintheresponseofcor-
tical bone (predominates at distal third of radius) com-
pared with trabecular bone (predominates at lumbar
spine, femoral neck, and total body bone mineral con-
tent). However, it is unclear why the control group
would show an effect at any site. The available data
do not allow this to be adequately addressed, and cau-
tion is needed in interpreting this analysis.
Limitations of the review
The number of studies contributing substantial data to
the meta-analysis was small.
2731-34 We therefore could
not fully assess the effects of important clinical factors
thatmightinfluenceoutcomesofsupplementation.For
example, we could not examine the interplay between
compliance, dose of cholecalciferol, and baseline vita-
min D levels. This interplay might have been able to
explain the lack of any difference in effect by dose
should the data have allowed this to be examined.
We could not adequately investigate sex differences,
anddataweretoofewtoassesseffectsaftersupplemen-
tation ceased. The cut-off of 35 nmol/L to define low
serum vitamin D concentration in subgroup analyses
was arbitrarily chosen based on the distribution of
data, so as to enable subgroup analyses. The main
studycontributing data to the subgroupwith low base-
linevitaminDlevel,however,includedaround20%of
participants with concentrations above 50 nmol/L.
Theeffectsizeswefoundmaythereforeunderestimate
the benefits of supplementation in deficient children
and adolescents. Further randomised controlled trials
are needed to determine the maximum benefit obtain-
able by supplementing vitamin D deficient children
and adolescents, whether benefits accrue with increas-
ing duration of supplementation, below what serum
vitamin D level benefits of supplementation can be
seen, and whether benefits persist after supplementa-
tion ceases. The effects in children and adolescents
overall at any site were not statistically significant,
and the observed effect sizes were also consistently
smallandunlikelytobeclinicallysignificant,withstan-
dardised mean differences ranging from 0.04 to 0.15
(table 2). Although it would take a large study with a
stronglypositiveresulttocauseanoticeableincreasein
effect size, the limited number of studiesand relatively
low overall numbers of participants could reduce the
robustness of our findings, and as results from further
studiesbecomeavailableitisimportantthatthisanaly-
sis is updated. It has been suggested that areal bone
mineral density only partly corrects for bone size and
thatadjustmentofbonemineralcontentforbonearea,
weight,andheightisdesirable.
58Onlyonestudy,how-
ever, reported any such data.
34 The study’s results
using this outcome were consistent with the meta-ana-
lysis results, with no statistically significant effect with
vitamin D supplements at either the hip or lumbar
spine. Only surrogate outcomes could be used in this
review because of the current lack of data on fracture
outcome. In future studies consideration should there-
fore be given to including childhood fractures as an
outcome. The use of fractures in older adult life as an
outcome will, however, remain problematic owing to
the lengthy follow-up periods that would be required.
Table 6 |Subgroup analyses of effects of vitamin D supplementation by pubertal status
Outcome
Prepubertal (Tanner stage 1 or 2) Postpubertal (Tanner stage 3 or 4)
No of studies*
No of
participants
Standardised mean difference†
(95%CI) No of studies*
No of
participants
Standardised mean difference†
(95% CI)
Hip bone mineral density 4 335 0.00 (−0.36 to 0.37) 3 304 0.17 (−0.07 to 0.40)
Lumbar spine bone mineral density 4 335 0.01 (−0.22 to 0.24) 3 304 0.16 (−0.07 to 0.40)
Total body bone mineral content 4 318 −0.01 (−0.24 to 0.22) 3 325 0.18 (−0.05 to 0.40)
Forearm bone mineral density 3 213 0.13 (−0.45 to 0.72) 2 214 0.06 (−0.23 to 0.34)
Outcome is percentage change from baseline.
*Where total number of studies compared exceeds six, studies contribute data to more than one subgroup.
†Standardised mean difference of 0.3 is regarded as small.
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Inconclusion,itisunlikelythatvitaminDsupplements
are beneficial in children and adolescents with normal
vitamin D levels. Our planned subgroup analyses by
baseline serum vitamin D level suggest that vitamin D
supplementation of deficient children and adolescents
couldresultinclinicallyusefulimprovements,particu-
larly in bone mineral density of the lumbar spine and
totalbody bonemineralcontent,but thisrequirescon-
firmation.
This paper is based on a Cochrane review published in the Cochrane
Library 2010, Issue 10 (see www.thecochranelibrary.com for
information). Cochrane reviews are regularly updated as new evidence
emerges and in response to feedback, and the Cochrane Library should
be consulted for the most recent version of the review.
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